Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step closer to reality after successfully closing a €28M Series A round. The spin-off of Université Catholique de Louvain coexists with Celyad and Promethera in a biotech cluster where cell therapy is the key protagonist.
The financing round, led by New Science Ventures, will boost Novadip’s lead compound Creost, a natural ready-to-use 3D bone replacement derived from adipose stem cells. These mesenchymal stem cells are obtained after isolation from a minimally invasive subcutaneous procedure. Their osteogenic structure reconstructs critical size bone defects without the use of any scaffolding, a similar concept to Biom’Up’s MatriBone.
Novadip’s technology originates from research lead by Prof Denis Dufrane and colleagues at St Luc University Hospital and the Université Catholique de Louvain. The company’s recent success also illustrates the University’s ability to spin-off a technology that will have a significant impact on patients.
Novadip, however, is not the only cell therapist in town.